Aditya Shreenivas MD MS
@AdityaSunavs
Assistant Professor Medical Oncology City of Hope Comprehensive Cancer Center
Thank you to @AdityaSunavs, of @cityofhope, for stopping by at #AACR25 to discuss the AK105-304 trial of penpulimab plus chemotherapy for recurrent/metastatic nasopharyngeal carcinoma! Check out our site for more from the meeting. @AACR #hncsm #oncology onclive.com/conference/aacr
We have another option to treat R/M Nasopharyngeal carcinoma. Honored to have presented AK105-304 phase III study at AACR. Special thanks to Akesobio team, City of Hope, all investigators and most importantly all pts. who contributed to this study. Stay tuned more to come!!
Happening NOW! IBM India Breast Meeting 2024 Precision Oncology Workshop in Breast Cancer! A full day of academic treat! Thank you all your support! @oncologician @RAJATRAJ @RFhospital @Vijayharibhakti @DatarCancer @PrashantK_PhD @RameshHarihara1
Hear ye hear ye! FDA grants accelerated approval to fam-trastuzumab deruxtecan-nxki for unresectable or metastatic HER2-positive solid tumors | FDA Her2 3+ 👉🔥🎯If it’s a marker, it’s a pan cancer marker: Tissue is not the issue fda.gov/drugs/resource…
Proud to be sharing that we have won an international investigator initiated project grant, one of the first in this region, in HNSCC w @s02shambhavi precision research fellow. @RFhospital @Vijayharibhakti @IylonOncology @DrSteveMartin @DrHaddadRobert #Mentor
Dr. David Craig joins the "Transcriptomics in Precision Oncology" panel chaired by @Dr_R_Kurzrock. Don't miss his insights on opportunities and limitations in this field and a deep dive into his favorite topic at #PMWC24: pmwcintl.com/session/jan-24…
A gamechanger ‼️📣 for KTRs with advanced CSCC. mTORi/prednisone pulse + Cemiplimab results in NO kidney rejection and durable efficacy! 🧐👀 @JCO_ASCO @DanaFarber @DanaFarberNews @evanlipson @DrNeilGross @nymurakami @LVRiella @Regeneron ascopubs.org/doi/10.1200/JC…
So amazing to meet you again Ray @Dr_R_Kurzrock You are the inspiration that keeps us going every day! 🙏🤗🌺 @AdityaSunavs
Special moments. Look whom I found in Milwaukee at MCW. Sewanti Limaye and her brother Aditya Shreeenivas— amongst the best precision oncologists on the planet. Aditya’s wife just had a beautiful baby boy— hence the visit from Sewanti all the way from India!
If it’s a target, it’s a pan-cancer target: Tissue is not the issue If it’s a solid tumor target, it’s a heme target (& vice versa) See our new review 🎯🎯 Illustrative case: Erdheim Chester disease (non-Langerhans histiocytosis)/CNS disease/ALK fusion->Alectinib response
Breakthrough research indeed and a proud moment for all of us here trying to make a mark! @PrashantK_PhD @SenduraiMani @oncologician @RAJATRAJ @mandri44 @siddhar99256978 @DrDarshanaSable @DrAkolkar @ullas_batra @AdityaSunavs @KDAHMumbai
Innovation and breakthrough research from India , happy to know this !
We then used machine learning with a random forest approach to build a model trained off of radiographic response (not survival). Training off response outcomes can help control for the many confounding factors that can affect overall survival
🚨 TOPAZ-1: 1L durvalumab+SoC chemo ➡️ significant ⬆️ OS vs. chemo alone in advanced biliary tract CA; also ⬆️ PFS, ORR. Stopped at interim analysis after meeting 1° endpoint. Awaiting official results. @OncoAlert astrazeneca.com/content/astraz… #cholangiocarcinoma
This may be a game changer. FDA Grants Breakthrough Device Designation for Biological Dynamics’ Early-stage Pancreatic Cancer Detection Test – San Diego Biotechnology Network businesswire.com/news/home/2021…
Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study - The Lancet Oncology thelancet.com/journals/lanon…
FOLFOXIRI‐Bevacizumab or FOLFOX‐Panitumumab in Patients with Left‐Sided RAS/BRAF Wild‐Type Metastatic Colorectal Cancer: A Propensity Score‐Based Analysis #MetastaticColorectalCancer #CombinationChemotherapy #Bevacizumab #Panitumumab #FOLFOX #FOLFOXIRI bit.ly/3rlxiMb